期刊
EXPERT OPINION ON EMERGING DRUGS
卷 19, 期 1, 页码 11-24出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728214.2014.870553
关键词
biliary cancer; chemotherapy; cholangiocarcinoma; molecular-targeted drugs
资金
- Lilly
- Taiho Pharmaceutical
- AstraZeneka
- GlaxoSmithKline
- Merck Serono
- Novartis
- Bayer
- Pfizer
- OncoTherapyScience
- Kowa
- Otsuka Pharmaceutical
- Boehringer Ingelheim Pharma
- Ono pharmaceutical, Yakult
- Eisai
- Kyowa Hakko Kirin
- Dainippon Sumitomo Pharma
- Chugai
- National Cancer Center Research and Development Fund
Introduction: The number of biliary cancer patients is small and it is often complicated by serious adverse events making it difficult for clinical studies to be performed on this cancer. However, researches for clarification of the mechanisms of onset and proliferation of biliary cancer and of the effects of drugs suppressing these mechanisms have been initiated recently, with the goal of establishing effective treatments. Areas covered: This review will cover epidemiological and biological features of biliary cancer, the efficacy and limitations of the existing methods of treatment, and current goals for the development of new treatment methods. Furthermore, the findings of pre-clinical studies on promising treatment targets and ongoing clinical studies are also reviewed, and perspectives for the future of treatment are discussed. Expert opinion: Following the recent increase in the interest in drug development, attempts at clarifying the molecular mechanisms underlying the onset and proliferation have been made proactively, accompanied by clinical studies on various molecular-targeted drugs for the treatment of this cancer. To demonstrate the efficacy of these drugs, it is essential to establish a system for efficient screening of patients carrying the molecular targets and to devise an excellent clinical study design.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据